ABO discrepancy resolution in two patients with acute myeloid leukemia presenting the transient weak expression of A antigen

Miola, Marcos Paulo; Oliveira, Tharsis Cardoso de; Guimaraes, A A; Mattos, Luiz Carlos de

doi:10.1016/j.htct.2022.01.015

Cited by 2 publications

(2 citation statements)

References 8 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although newly developed genetic variants of the ABO gene could be suspected, ABO genotyping performed on patients with this phenomenon did not reveal any newly introduced genetic abnormalities in these individuals, which was similar to our data. 15 , 16 In addition, other genes known to be involved in ABO gene expression were also investigated, and mutations of RUNX1 and GATA2 were suggested to be related with the reduction of erythrocyte A antigen expression. 10 , 11 RUNX1 encodes a Runt-related transcription factor, which plays a role in regulation of hematopoiesis.…”

Section: Discussionmentioning

confidence: 99%

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

Choi,

Kim,

Suh

et al. 2024

Blood Advances

View full text Add to dashboard Cite

The ABO antigen weakness is rarely observed in ABO typing for transfusion. Hematologic diseases and associated gene mutations have been suggested as potential causes of this phenomenon, yet the precise etiology has not been elucidated. Through ABO typing and genetic analysis data conducted over 7 years, we have reconfirmed the association between ABO antigen weakness and hematologic diseases, especially acute myeloid leukemia (odds ratio (OR) 2.55, 95% confidence interval (CI) 1.12-5.83) and myelodysplastic syndrome (OR 6.94, 95% CI 2.86-16.83), and discovered previously unidentified candidate genes, CEBPA (OR 43.70, 95% CI 18.12-105.40), NRAS (OR 3.37, 95% CI 1.46-7.79), U2AF1 (OR 8.12, 95% CI 2.86-23.03) and PTPN11 (OR 4.52, 95% CI 1.51-13.50), seemingly associated with this phenomenon. Among these, CEBPA double mutations displayed a significant association, with ABO antigen weakness being observed in 20 out of the 25 individuals (80.0%) possessing these mutations. From this study, new factors associated with ABO antigen weakness have been identified.

show abstract

Section: Discussionmentioning

confidence: 99%

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

Choi,

Kim,

Suh

et al. 2024

Blood Advances

View full text Add to dashboard Cite

show abstract

“…21,22 A case of a person with O blood group and weak anti-A1 as compared to anti-B antibodies was reported. 23 The case of the person with B blood group without anti-A antibodies in the serum due to the low level of gamma-globulin has been described. 19,24 Type II discrepancy was reported, when anti-B antibodies were revealed by serum grouping, however erythrocytes were not agglutinated by anti-A antibody at room temperature and 37 °C, nevertheless erythrocytes were agglutinated by anti-A1 lectin.…”

Section: Discussionmentioning

confidence: 99%

Resolving discrepancies in forward and reverse ABO blood group typing

Grigorovich,

Olexiyovich,

Solomonivna

et al. 2023

Scripta Medica

View full text Add to dashboard Cite

Background/Aim: There is a need of investigation of high frequency of the cases of ABO discrepancy revealed by forward and reverse typing. The aim of the study was to reveal optimal methods for detection of weak subgroups of group A and B antigens on erythrocytes. Methods: Sixteen persons with A blood group and anti-B antibody adsorbing ability (weak Bel, Bm and B3 antigens), 5 persons with B blood group and anti-A antibody adsorbing ability (weak Ax antigen) and 2 persons with O blood group and anti-B antibody adsorbing ability (weak Bel antigen) were investigated as the cases of type II-III of ABO discrepancy and weak B antigen. Liquid chromatography, agglutination, inhibition of agglutination and adsorption reactions at 4 °C and 37 °C with prolonged incubation (12 hours) were used in the study. Results: The persons with A blood group revealed by forward typing at 4 °C and O blood group detected by reverse typing at 37 °C showed the ability of the erythrocytes to adsorb anti-B antibody. The persons with B blood group revealed by forward typing with presence of anti-B antibodies reactive at 37 °C showed the ability of erythrocytes to adsorb anti-A antibody. Prolonged incubation at reverse typing, adsorption-elution tests, inhibition of haemagglutination and liquid chromatography were used to define blood group specificity. Conclusion: Prolonged incubation during reverse typing at 4 °C and 37 °C, adsorption at 4 °C, heat elution and liquid chromatography might help to detect blood group type in cases of type II-III of ABO discrepancy.

show abstract

ABO discrepancy resolution in two patients with acute myeloid leukemia presenting the transient weak expression of A antigen

Cited by 2 publications

References 8 publications

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

Resolving discrepancies in forward and reverse ABO blood group typing

Contact Info

Product

Resources

About